LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?
- 5 October 2022
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 37 (11) , 2193
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2Journal of the American Chemical Society, 2022
- Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s diseaseScience Translational Medicine, 2022
- R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophilsActa Neuropathologica, 2021
- LRRK2 kinase in Parkinson's diseaseScience, 2018
- Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPaseseLife, 2016